
As healthcare costs continue to rise, accurate cost-effectiveness estimates are crucial. However, estimating the costs and outcomes of different interventions is complicated by uncertainty.
In model-based health economic evaluations (HEEs), uncertainty can arise from limited data, methodological limitations, and variability in clinical outcomes.
A recent review identified 80 methods for identifying, analyzing, and communicating uncertainty in HEEs. Quantifying uncertainty wherever possible is crucial to ensure accurate and unbiased cost-effectiveness estimates, ultimately leading to optimal allocation of healthcare resources
Recent Posts
Advancing Participatory Arts Health in Dutch Care Systems
Participatory arts health is gaining recognition as a valuable complement to traditional medical care, supporting both physical and psychosocial well-being for people living with chronic conditions and those at the end of life. In this article we explore how creative, participatory approaches ...
Advancing Tarlatamab for Small Cell Lung Cancer Treatment
New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer
Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
Inflation Reduction Act Impact on Clinical Trial Investment Trends
The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.